A detailed history of Marshall Wace, LLP transactions in Repligen Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 237,222 shares of RGEN stock, worth $38.2 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
237,222
Previous 364,551 34.93%
Holding current value
$38.2 Million
Previous $46 Million 23.18%
% of portfolio
0.05%
Previous 0.06%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.79 - $167.35 $15.3 Million - $21.3 Million
-127,329 Reduced 34.93%
237,222 $35.3 Million
Q2 2024

Aug 14, 2024

BUY
$120.0 - $182.95 $463,680 - $706,918
3,864 Added 1.07%
364,551 $46 Million
Q1 2024

May 15, 2024

BUY
$170.78 - $208.42 $6.82 Million - $8.32 Million
39,910 Added 12.44%
360,687 $66.3 Million
Q4 2023

Feb 14, 2024

SELL
$114.17 - $185.35 $1.54 Million - $2.5 Million
-13,502 Reduced 4.04%
320,777 $57.7 Million
Q3 2023

Nov 14, 2023

SELL
$138.78 - $176.51 $16 Million - $20.3 Million
-115,209 Reduced 25.63%
334,279 $53.2 Million
Q2 2023

Aug 14, 2023

BUY
$138.42 - $180.31 $36.4 Million - $47.5 Million
263,259 Added 141.36%
449,488 $63.6 Million
Q1 2023

May 15, 2023

BUY
$154.26 - $198.1 $19 Million - $24.4 Million
123,078 Added 194.89%
186,229 $31.4 Million
Q4 2022

Feb 14, 2023

SELL
$162.42 - $220.56 $21.3 Million - $28.9 Million
-131,164 Reduced 67.5%
63,151 $10.7 Million
Q3 2022

Nov 14, 2022

SELL
$160.42 - $256.21 $28.6 Million - $45.7 Million
-178,562 Reduced 47.89%
194,315 $36.4 Million
Q2 2022

Aug 15, 2022

BUY
$140.68 - $188.02 $1.21 Million - $1.62 Million
8,630 Added 2.37%
372,877 $60.6 Million
Q1 2022

May 16, 2022

SELL
$161.19 - $257.96 $1.67 Million - $2.68 Million
-10,386 Reduced 2.77%
364,247 $68.5 Million
Q4 2021

Feb 14, 2022

SELL
$247.59 - $304.47 $36 Million - $44.3 Million
-145,497 Reduced 27.97%
374,633 $99.2 Million
Q3 2021

Nov 15, 2021

SELL
$194.77 - $324.21 $35.6 Million - $59.3 Million
-182,784 Reduced 26.0%
520,130 $150 Million
Q2 2021

Aug 13, 2021

SELL
$165.87 - $220.95 $39.9 Million - $53.2 Million
-240,810 Reduced 25.52%
702,914 $140 Million
Q1 2021

May 17, 2021

SELL
$180.37 - $226.26 $97 Million - $122 Million
-537,556 Reduced 36.29%
943,724 $183 Million
Q4 2020

Feb 16, 2021

BUY
$148.08 - $206.57 $84.9 Million - $118 Million
573,604 Added 63.19%
1,481,280 $284 Million
Q3 2020

Nov 16, 2020

BUY
$122.51 - $158.27 $32.4 Million - $41.9 Million
264,563 Added 41.14%
907,676 $134 Million
Q2 2020

Aug 13, 2020

BUY
$94.33 - $140.48 $7.41 Million - $11 Million
78,601 Added 13.92%
643,113 $79.5 Million
Q1 2020

May 15, 2020

BUY
$84.96 - $109.14 $48 Million - $61.6 Million
564,512 New
564,512 $54.5 Million
Q4 2019

Feb 14, 2020

SELL
$73.84 - $93.08 $471,468 - $594,315
-6,385 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$76.65 - $95.51 $7.93 Million - $9.89 Million
-103,501 Reduced 94.19%
6,385 $490,000
Q2 2019

Aug 14, 2019

BUY
$54.2 - $85.95 $5.96 Million - $9.44 Million
109,886 New
109,886 $9.45 Million
Q1 2019

May 14, 2019

SELL
$49.45 - $62.8 $205,959 - $261,562
-4,165 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$48.26 - $68.88 $201,002 - $286,885
4,165 New
4,165 $219,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.93B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.